In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.
The efficacy of anidulafungin, an echinocandin antifungal agent with potent anti-Candida activity, in treating esophageal candidiasis was tested in a double-blind study versus oral fluconazole. Isolates were identified and tested for susceptibility. Candida albicans represented >90% of baseline isolates. The MIC(90) of anidulafungin for all strains was 0.06 mg/liter.
Pfaller
M A
MA
Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
Hollis
R
R
Goldstein
B P
BP
Messer
S
S
Diekema
D
D
Henkel
T
T
D000077612:Anidulafungin; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects*; D002177:Candidiasis / Q000382:microbiology*; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D025141:Drug Resistance, Fungal; D054714:Echinocandins / Q000494:pharmacology*; D004935:Esophageal Diseases / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests
D000935:Antifungal Agents; D054714:Echinocandins; D000077612:Anidulafungin